Cervenka, Iris and Al Rahmoun, Marie and Mahamat-Saleh, Yahya and Fournier, Agnes and Boutron-Ruault, Marie-Christine and Severi, Gianluca and Caini, Saverio and Palli, Domenico and Ghiasvand, Reza and Veierod, Marit B. and Botteri, Edoardo and Tjonneland, Anne and Olsen, Anja and Fortner, Renee T. and Kaaks, Rudolf and Schulze, Matthias B. and Panico, Salvatore and Trichopoulou, Antonia and Dessinioti, Clio and Niforou, Katerina and Sieri, Sabina and Tumino, Rosario and Sacerdote, Carlotta and Bueno-de-Mesquita, Bas and Sandanger, Torkjel M. and Colorado-Yohar, Sandra and Sanchez, Maria J. and Gil Majuelo, Leire and Lujan-Barroso, Leila and Ardanaz, Eva and Merino, Susana and Isaksson, Karolin and Butt, Salma and Ljuslinder, Ingrid and Jansson, Malin and Travis, Ruth C. and Khaw, Kay-Tee and Weiderpass, Elisabete and Dossus, Laure and Rinaldi, Sabina and Kvaskoff, Marina (2020) Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 146 (12). pp. 3267-3280. ISSN 0020-7136, DOI https://doi.org/10.1002/ijc.32674.
Full text not available from this repository.Abstract
Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country-specific self-administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline-significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00-1.26), with no detected heterogeneity across countries (p(homogeneity) = 0.42). This risk increased linearly with duration of use (p(trend) = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97-1.43), which was heterogeneous across countries (p(homogeneity) = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations.
| Item Type: | Article |
|---|---|
| Funders: | Dutch Prevention Funds, Medical Research Council [Grant No: MR/N003284/1], Health Research Fund [Grant No: FIS) Pl13/00061, Pl13/01162] |
| Uncontrolled Keywords: | Cohort studies; Cutaneous melanoma; Epidemiology; Hormonal treatments; Menopausal hormone therapy; Oral contraceptives |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 04 Nov 2024 00:22 |
| Last Modified: | 04 Nov 2024 00:22 |
| URI: | http://eprints.um.edu.my/id/eprint/36612 |
Actions (login required)
 |
View Item |
